drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous, gene-modified T cells engineered with the Sleeping Beauty transposon/transposase system to stably express patient-specific, tumor-reactive T-cell receptors targeting mutation-derived neoantigen peptides presented on HLA; upon infusion, these cells activate TCR-CD3 signaling to mediate cytotoxic killing (perforin/granzyme) and may generate immunologic memory.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified with the Sleeping Beauty transposon/transposase system to stably express patient-specific, tumor-reactive TCRs that recognize mutation-derived neoantigen peptides presented on HLA (primarily MHC I). Upon infusion, engagement of the TCR-CD3 complex triggers activation, clonal expansion, cytokine release, and cytotoxic killing of tumor cells via perforin/granzyme, with potential development of immunologic memory.
drug_name
Neoantigen-specific TCR-T cell drug product
nct_id_drug_ref
NCT05292859